In a recent study, Tran et al. [87] have shown that pazopanib, IL-6, IL-8, VEGF, osteopontin, E-selectin, and hepatocyte growth factor (HGF) levels were associated with continuous tumor shrinkage with pazopanib treatment in phase 1 clinical trials. Here, HGF is linked to neoplasm.